Eifiona Wood


Eifiona is a Senior Research Fellow in Pharmacoeconomics at the Centre for Health Economics and Medicine Evaluation at Bangor University. She holds a Bachelors degree in Pharmacy from the University of Wales Institute of Science and Technology, Cardiff (1992) and in 2005 completed a Masters degree in Health Economics and Management at the University of Sheffield.

After graduating from Cardiff, Eifiona spent 8 years as a hospital pharmacist specialising in oncology, provision of clinical services, funding and business support in both the UK and Australia. Following on from this, Eifiona pursued a career in health economics within the pharmaceutical industry and the consulting environment, working on a wide range of projects including developing and adapting health economic models, budget impact models, cost of illness studies, HTA submissions, orphan drugs and environmental analyses.

She is experienced in a variety of therapy areas including oncology, neurology, respiratory, fertility and mental health. Eifiona also has widespread experience in the development of value communications, manuscripts and posters, and has co-authored peer-reviewed papers in health economics.

Eifiona joined CHEME in 2015 and is currently working on a range of pharmacoeconomic projects, including two neurology trials on treatments for sciatica. She also acts as the deputy health economist to the New Medicines Group, an advisory subgroup of the All Wales Medicines Strategy Group.


Lowin J, Bergman A, Chaudhuri KR, Findley LJ, Roeder C, Schifflers M, Wood E et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK. J Med Econ 2011; 14(5):584-593.

Findley LJ, Wood E, Lowin J, Roeder C, Bergman A, Schifflers M. The economic burden of advanced Parkinson's disease: an analysis of a UK patient dataset. J Med Econ 2011; 14(1):130-139.

Asukai Y, Valladares A, Camps C, Wood E, Taipale K, Arellano J et al. Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer 2010; 10:26. doi: 10.1186/1471-2407-10-26.:26-10.

Hind D, Wyld L, Wood E, Beverley C, Reed MW. Axillary staging for operable primary breast cancer. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD004561. DOI: 10.1002/14651858.CD004561.pub2.